Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
ZTS Zoetis Inc
HMPT Home Point Capital Inc
KWR Quaker Chemical Corp
TWO Two Harbors Investment Corp
BV Brightview Holdings Inc
PBPB Potbelly Corp
RLJ RLJ Lodging Trust
LHCG LHC Group Inc
KW Kennedy-Wilson Holdings Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Closing Price
$116.08
Day's Change
0.30 (0.26%)
Bid
--
Ask
--
B/A Size
--
Day's High
116.18
Day's Low
114.16
Volume
(Average)
Volume:
5,803,752

10-day average volume:
6,301,980
5,803,752

ABBV's position in the Biotechnology industry

Industry PeersABBVGILDVRTXREGNSGEN

Summary

Company ProfileAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are...
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and...
Go to GILD summary
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing...
Go to VRTX summary
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The...
Go to REGN summary
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the...
Go to SGEN summary
52-Week Change

VS. INDUSTRY
35.89%
-14.11%
-21.07%
-9.90%
-17.35%
Market Cap

VS. INDUSTRY
$204.9B
$83.8B
$55.2B
$53.1B
$24.7B
Beta

VS. INDUSTRY
0.8
0.4
0.7
0.2
0.9
Dividend Yield

VS. INDUSTRY
4.48%
4.27%
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
42.84x
323.40x
20.28x
14.11x
37.78x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$45.8B
$25.6B
$6.4B
$9.2B
$2.3B
Profit Margin

VS. INDUSTRY
10.09%
1.07%
43.06%
43.53%
29.07%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
-2.82%
-61.76%
--
40.78%
--
Revenue Growth (TTM)

VS. INDUSTRY
37.69%
12.54%
33.10%
25.66%
137.76%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.